Suppr超能文献

罗托菌素 A 通过下调 Slug 抑制上皮-间充质转化来抑制非小细胞肺癌细胞生长和转移。

Rosthorin A inhibits non-small cell lung cancer cell growth and metastasis through repressing epithelial-mesenchymal transition via downregulating Slug.

机构信息

Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University.

School of Pharmaceutical Sciences, Jiangnan University, Wuxi.

出版信息

Anticancer Drugs. 2020 Nov;31(10):997-1003. doi: 10.1097/CAD.0000000000000973.

Abstract

Lung cancer always ranks first in the number of cancer deaths every year, accounting for 18.4% of total cancer deaths in 2018. Metastasis is the main cause of death in lung cancer patients. The identification of bioactive components of traditional Chinese medicine is very important for the development of novel reagents against non-small cell lung cancer (NSCLC). Rosthorin A has originated from Rabdosia rosthornii (Diels) Hara which excerpts from 'Chinese materia medica', and is known to have 'clear heat phlegm' properties in the folk. Little is known about the biological functions and mechanisms of Rosthorin A in cancer cells at present. The role of EMT in metastasis of a tumor cell is self-evident. Slug is an important EMT inducer, which is related to the development of lung cancer. Cell growth, clone assay, cell migration, cell invasion, and protein expression, and NSCLC transplanted tumor growth were performed in A549, H1299, and H1975 cells. Rosthorin A significantly inhibited the growth of NSCLC cells, it could prolong the survival of nude mice. Rosthorin A inhibited the migration and invasion of A549, H1299, and H1975 cells. Rosthorin A up-regulated E-cadherin expression level and down-regulated the expression of β-catenin, N-cadherin, vimentin, Slug, and Twist. Rosthorin A could promote the expression of E-cadherin and inhibit the development of EMT by downregulating Slug, to inhibit the development and metastasis of NSCLC cells. In summary, Rosthorin A could be used as a promising candidate for the treatment of NSCLC patients with recurrence and metastasis.

摘要

肺癌一直是每年癌症死亡人数中排名第一的癌症,占 2018 年癌症总死亡人数的 18.4%。转移是肺癌患者死亡的主要原因。鉴定中药的生物活性成分对于开发针对非小细胞肺癌(NSCLC)的新型试剂非常重要。罗司酮 A 来源于《中华本草》中的冬凌草,民间有“清热化痰”的功效。目前,人们对罗司酮 A 在癌细胞中的生物学功能和机制知之甚少。EMT 在肿瘤细胞转移中的作用不言而喻。Slug 是 EMT 的重要诱导因子,与肺癌的发生有关。在 A549、H1299 和 H1975 细胞中进行细胞生长、克隆实验、细胞迁移、细胞侵袭和蛋白表达以及 NSCLC 移植瘤生长实验。罗司酮 A 显著抑制 NSCLC 细胞的生长,可延长裸鼠的存活时间。罗司酮 A 抑制 A549、H1299 和 H1975 细胞的迁移和侵袭。罗司酮 A 上调 E-钙黏蛋白表达水平,下调 β-连环蛋白、N-钙黏蛋白、波形蛋白、Slug 和 Twist 的表达。罗司酮 A 通过下调 Slug 促进 E-钙黏蛋白的表达,抑制 EMT 的发生,从而抑制 NSCLC 细胞的发生和转移。综上所述,罗司酮 A 可作为治疗 NSCLC 患者复发和转移的有前途的候选药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01af/7566306/cc60872c825c/acd-31-0997-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验